Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Dig Dis Sci ; 67(11): 5107-5115, 2022 11.
Article in English | MEDLINE | ID: mdl-35122589

ABSTRACT

BACKGROUND AND AIMS: To determine prevalence and clinical utility of pathogenic germline variants (PGV) in gastric and esophageal cancer patients using universal genetic testing approach. METHODS: We undertook a prospective study of germline sequencing using an > 80 gene next-generation sequencing platform among patients with gastric and esophageal cancers receiving care at Mayo Clinic Cancer Center between April 1, 2018, and March 31, 2020. Patients were not selected based on cancer stage, family history of cancer, ethnicity, or age. Family cascade testing was offered at no cost. RESULTS: A total of 96 patients were evaluated. Median age was 66 years, 80.2% were male, 89.6% were white. Nearly 39% of the cohort had esophageal cancer, 35.4% gastric cancer and 26% gastroesophageal junction cancers. Approximately half (52%) of the patients had metastatic disease. Pathogenic germline variants (PGV) were detected in 15.6% (n = 15) patients. The prevalence of PGV was 10.8% in esophageal cancer, 17.6% in gastric cancer and 20% in gastroesophageal cancer. Eighty percent of patients with a positive result would not have been detected by screening with standard guidelines for genetic testing. Most PGV detected included genes with high and moderate penetrance related to DNA damage response including BRCA1, BRCA2, PALB2 and ATM. CONCLUSIONS: Universal multi-gene panel testing in gastric and esophageal cancers was associated with detection of heritable mutations in 15% of patients. The majority of PGV would not be detected with current screening guidelines and are related to DNA damage response.


Subject(s)
Esophageal Neoplasms , Stomach Neoplasms , Humans , Male , Aged , Female , Prospective Studies , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/epidemiology , Esophageal Neoplasms/genetics , Stomach Neoplasms/diagnosis , Stomach Neoplasms/epidemiology , Stomach Neoplasms/genetics , Germ-Line Mutation , Genetic Testing , Germ Cells , Genetic Predisposition to Disease
2.
Sci Transl Med ; 2(23): 23ra20, 2010 Mar 17.
Article in English | MEDLINE | ID: mdl-20375004

ABSTRACT

The predisposition for scleroderma, defined as fibrosis and hardening of the skin, is poorly understood. We report that stiff skin syndrome (SSS), an autosomal dominant congenital form of scleroderma, is caused by mutations in the sole Arg-Gly-Asp sequence-encoding domain of fibrillin-1 that mediates integrin binding. Ordered polymers of fibrillin-1 (termed microfibrils) initiate elastic fiber assembly and bind to and regulate the activation of the profibrotic cytokine transforming growth factor-beta (TGFbeta). Altered cell-matrix interactions in SSS accompany excessive microfibrillar deposition, impaired elastogenesis, and increased TGFbeta concentration and signaling in the dermis. The observation of similar findings in systemic sclerosis, a more common acquired form of scleroderma, suggests broad pathogenic relevance.


Subject(s)
Microfilament Proteins/genetics , Mutation/genetics , Scleroderma, Systemic/congenital , Scleroderma, Systemic/genetics , Skin/pathology , Biopsy , Cell Adhesion , Cell Movement , Collagen/metabolism , DNA Mutational Analysis , Elastin/metabolism , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Family , Female , Fibrillin-1 , Fibrillins , Humans , Immunohistochemistry , Male , Mesoderm/pathology , Microfibrils/metabolism , Microfibrils/pathology , Microfilament Proteins/metabolism , Pedigree , Phenotype , Scleroderma, Systemic/pathology , Signal Transduction , Skin/ultrastructure , Syndrome , Transforming Growth Factor beta/metabolism
4.
Acad Med ; 76(10): 979-80, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11669088
5.
Mayo Clin Proc ; 76(7): 749-52, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11444409

ABSTRACT

Calciphylaxis is a rare disorder of small-vessel calcification and cutaneous infarction associated with chronic renal failure. Rare cases of calciphylaxis not associated with chronic renal failure have been reported with breast cancer, hyperparathyroidism, and alcoholic cirrhosis. To our knowledge, we report the first case of calciphylaxis without chronic renal failure associated with cholangiocarcinoma and the first attempt to treat calciphylaxis with vitamin K. A 56-year-old woman presented with necrotic leg ulceration. She was treated initially with low-molecular-weight heparin, with no effect. A coagulation work-up showed vitamin K deficiency. During vitamin K therapy, the patient had fulminant progression of the calciphylaxis. She died, and an autopsy showed metastatic cholangiocarcinoma. Thrombosis and protein C deficiency have been implicated in the pathophysiology of calciphylaxis. Functional protein C deficiency may be one of several factors contributing to the development of calciphylaxis. Vitamin K therapy was ineffective in our patient and may have been detrimental.


Subject(s)
Adenocarcinoma/pathology , Anticoagulants/therapeutic use , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic , Calciphylaxis/drug therapy , Calciphylaxis/etiology , Cholangiocarcinoma/pathology , Heparin, Low-Molecular-Weight/therapeutic use , Liver Neoplasms/pathology , Lung Neoplasms/secondary , Neoplasms, Multiple Primary/pathology , Vitamin K Deficiency/complications , Vitamin K Deficiency/drug therapy , Vitamin K/therapeutic use , Biopsy , Calciphylaxis/diagnosis , Fatal Outcome , Female , Humans , Leg Ulcer/etiology , Leg Ulcer/pathology , Lung Neoplasms/diagnosis , Middle Aged , Necrosis , Prognosis , Sepsis/etiology , Vitamin K Deficiency/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...